Download presentation
Presentation is loading. Please wait.
Published by하영 저 Modified over 5 years ago
1
Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation to Treat Patients with Poor-Risk, Relapsed, or Refractory Multiple Myeloma George E. Georges, Michael B. Maris, David G. Maloney, Brenda M. Sandmaier, Mohamed L. Sorror, Judith A. Shizuru, Thoralf Lange, Edward D. Agura, Benedetto Bruno, Peter A. McSweeney, Michael A. Pulsipher, Thomas R. Chauncey, Marco Mielcarek, Barry E. Storer, Rainer Storb Biology of Blood and Marrow Transplantation Volume 13, Issue 4, Pages (April 2007) DOI: /j.bbmt Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions
2
Figure 1 Cumulative incidence of GVHD after unrelated HCT (n = 24). (A) Acute GVHD: 67% all grades of GVHD, 54% grade II, and 13% grade III GVHD by day 120. (B) Chronic extensive GVHD, 75% incidence at 3 years. (C) NRM, 21% at 3 years. Biology of Blood and Marrow Transplantation , DOI: ( /j.bbmt ) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions
3
Figure 2 OS (solid line) and PFS (dotted line) after nonmyeloablative conditioning and unrelated HCT for (A) all patients studied (n = 24), (B) recipients of tandem autologous-unrelated HCT (n = 13), and (C) patients proceeding directly to unrelated HCT (n = 11). Biology of Blood and Marrow Transplantation , DOI: ( /j.bbmt ) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions
4
Figure 3 Risk factors for OS after nonmyeloablative conditioning and unrelated HCT for all 24 patients. (A) CCI score [15] of 0 (solid line, n = 17), or ≥ 1 (dashed line, n = 7) (P = .03). (B) Disease-sensitive (solid line, n = 7) or refractory (dashed line, n = 17) to the most recent chemotherapy regimen (P = .02). (C) Failure of previous autologous HCT (dashed line, n = 14) or no previous/no failure of previous autologous HCT (solid line, n = 10) (P = .10). Biology of Blood and Marrow Transplantation , DOI: ( /j.bbmt ) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.